1. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91-100.
2. Cystic Fibrosis Foundation. 2019 Patient Registry Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2019. Accessed July 02, 2026. https://www.cff.org/sites/default/files/2021-10/2019-Patient-Registry-Annual-Data-Report.pdf.
3. Cystic Fibrosis Foundation. CFF.org. Pseudomonas. Accessed July 02, 2026. https://www.cff.org/managing-cf/pseudomonas.
4. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-689.
5. Malhotra S, Hayes D Jr, Wozniak DJ. Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clin Microbiol Rev. 2019;32(3):e00138-18.
6. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest. 2009;135(5):1223-1232.
7. Pritt B, O’Brien L, Winn W. Mucoid Pseudomonas in cystic fibrosis. Am J Clin Pathol. 2007;128(1):32-34.
8. Cunningham JC, Taussig LM. Respiratory system. In: An Introduction to Cystic Fibrosis: For Patients and Their Families. 6th ed. Bethesda, MD: Cystic Fibrosis Foundation; 2013:41-58.
9. Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros. 2013;12(2):130-140.